Valuation: Valneva SE

Market Cap 471M 528M 439M 399M 752M 51.16B 759M 5.27B 2.06B 26.07B 1.98B 1.94B 83.53B P/E 2026 *
-5.7x
P/E 2027 * 9x
Enterprise Value 605M 678M 564M 513M 965M 65.68B 974M 6.77B 2.65B 33.46B 2.55B 2.49B 107B EV / Sales 2026 *
4.01x
EV / Sales 2027 * 1.88x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day-4.68%
1 week-8.30%
Current month-8.30%
1 month-14.01%
3 months+8.75%
6 months-3.50%
Current year-33.16%
1 week 2.42
Extreme 2.418
2.66
1 month 2.42
Extreme 2.418
2.94
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Date Insider Type Main position Quantity % Market Cap. Importance
1/27/26 Sell

Chief Technology Officer

11,800 0.0069%
1/26/26 Sell

Chief Financial Officer

11,800 0.0069%
1/19/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-4.68%-8.30%-45.98%-53.84% 553M
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -4.27%-2.75%+29.84%+124.36% 38.67B
Weighted average by Cap. -4.86%-1.88%+44.57%+136.15%

Financials

2026 *2027 *
Net sales 151M 169M 141M 128M 241M 16.39B 243M 1.69B 661M 8.35B 635M 622M 26.76B 283M 318M 264M 240M 452M 30.76B 456M 3.17B 1.24B 15.67B 1.19B 1.17B 50.22B
Net income -81.11M -90.94M -75.63M -68.75M -129M -8.81B -131M -907M -355M -4.49B -341M -334M -14.38B 53.07M 59.5M 49.48M 44.98M 84.64M 5.76B 85.48M 594M 232M 2.94B 223M 219M 9.41B
Net Debt 134M 150M 125M 113M 213M 14.52B 215M 1.5B 585M 7.4B 563M 551M 23.7B 62.48M 70.04M 58.25M 52.95M 99.64M 6.78B 101M 699M 273M 3.46B 263M 257M 11.07B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
26-10-08 €2.485 -4.68% 796,073
26-10-07 €2.607 +1.64% 250,616
26-10-06 €2.565 +0.47% 511,072
26-10-05 €2.553 +0.87% 385,656
26-10-02 €2.531 -3.06% 620,259
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.485EUR
Average target price
6.193EUR
Spread / Average Target
+149.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE